Expect the unexpected: fulminant myocardial cytotoxic Injury from Trabectedin

Expect the unexpected: fulminant myocardial cytotoxic Injury from Trabectedin

Abstract Background Trabectedin (Tbt) is an alkylating agent prescribed for soft tissue sarcomas after treatment failure of first line agents. While cardiomyopathy can occur with Tbt treatment after anthracycline exposure, Tbt-induced fulminant myocardial cytotoxic injury in the setting of other sys...

Full description

Bibliographic Details
Main Authors: Annie J. Tsay, Mohan Satish, Elizabeth Corley, Ashley Ezema, Neisha DeJesus, Stephen Wisely, Eileen McAleer, Chen Zhang, Su Yuan, Edwin Homan, Jennifer E. Liu, Jonathan W. Weinsaft, Sandra D’Angelo, Stephanie A. Feldman, Angel T. Chan
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Cardio-Oncology
Subjects:
Trabectedin
Cardiotoxicity
Cardio-oncology
Chemotherapy
Cancer
Sarcoma
Online Access:https://doi.org/10.1186/s40959-024-00257-7

Internet

https://doi.org/10.1186/s40959-024-00257-7

Similar Items